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Abstract
Increasing evidence indicates that Parkinson’s disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular
networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide
biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common
dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to
seed genes and their involvement in common biological pathways. Quantitative polymerase chain reaction assays revealed
that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in
192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and
Prognostic Biomarkers in Parkinson’s disease (PROBE). The results from this study reinforce the idea that shared molecular
networks between PD and T2DM provides an additional source of biologically meaningful biomarkers. Evaluation of this
biomarker in de novo PD patients and in a larger prospective longitudinal study is warranted.
Citation: Santiago JA, Scherzer CR, Potashkin JA (2014) Network Analysis Identifies SOD2 mRNA as a Potential Biomarker for Parkinson’s Disease. PLoS ONE 9(10):
e109042. doi:10.1371/journal.pone.0109042
Editor: Peter Csermely, Semmelweis University, Hungary
Received June 3, 2014; Accepted September 5, 2014; Published October 3, 2014
Copyright:  2014 Santiago et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This study was funded by the U.S. Army Medical Research and Materiel Command under award numbers W81XWH-09-0708 and W81XWH13-1-0025 to
J.A.P. C.R.S. is funded by National Institutes of Health (NIH) grants R01 NS064155, R01 AG044113, U01 NS082157, U01 AT000613, P01 NS058793, the Harvard
NeuroDiscovery Center, the Michael J. Fox Foundation, and the M.E.M.O. Hoffman Foundation. The Harvard Biomarker Study is supported by the Harvard
NeuroDiscovery Center (HNDC), the Parkinson’s Disease Biomarkers Program (PDBP) grant U01 NS082157 of the National Institute of Neurological Disorders and
Stroke (NINDS), and the Massachusetts Alzheimer’s Disease Research Center (ADRC) P50 AG005134 grant of the National Institute on Aging. C.R.S. has
collaborated with DiaGenic, Pfizer, Opko, and Proteome Sciences. Opinions, conclusions, interpretations and recommendations are those of the authors and are
not necessarily endorsed by the U.S. Army. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: C.R.S. has collaborated with DiaGenic, Pfizer, Opko, and Proteome Sciences. This does not alter the authors’ adherence to PLOS ONE
policies on sharing data and materials.
* Email: judy.potashkin@rosalindfranklin.edu
Introduction
Accumulating epidemiological evidence suggests a risk of PD
among patients with T2DM [1–3], reviewed in [4,5]. However,
there remains conflict among some studies. For example, several
groups suggest an inverse association between PD and T2DM
[6,7] and other studies have not found a significant association
[8,9]. Despite this discrepancy, T2DM is associated with more
severe symptoms in PD. T2DM contributes to postural instability
and gait difficulty in PD [10] and insulin resistance is associated
with an increased risk of dementia in PD [11]. Besides insulin
resistance, dysregulation in other shared biological pathways
including mitochondrial dysfunction, endoplasmic reticulum (ER)
stress and inflammation may be a plausible explanation for the
coexistence of both aging diseases [4,12].
Both PD and T2DM are considered idiopathic diseases in
which a combination of genetic and environmental factors are
likely to be involved in the disease pathogenesis. In fact, genetic
risk factors identified by genome-wide association studies (GWAS)
accounts for approximately 5–10% of the PD and T2DM cases
[4,5]. Several system-biology approaches including animal models
and network analysis have been used to understand the molecular
mechanisms underlying the linkage between PD and T2DM
[5,13,14]. For example, diabetic mice treated with 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) displayed an exacer-
bated neurodegeneration accompanied by inflammation and ER-
stress [13]. In parallel, an integrative network-based approach
restricted to data from only GWAS was used to investigate the
potential molecular framework linking PD and T2DM and to
identify potential biomarkers with clinical applicability. Results
from these studies identified the amyloid precursor protein (APP)
mRNA as a biomarker for PD [15]. Similarly, a network approach
identified PTPN1 mRNA as a diagnostic biomarker in progressive
supranuclear palsy, an atypical parkinsonian disorder sometimes
misdiagnosed as PD [16].
Here we expanded our previous network analysis to integrate
data from publicly available and curated disease-gene databases to
further investigate the connection between both diseases. The
disease-gene associations derived from the databases included in
this study are not strictly determined by GWAS, thus allowing the
exploration of other potentially interesting genes that may have a
more modest association. Because PD and T2DM are sporadic
and environmental factors play a role in disease etiology and
development, it is important to use databases that include genetic
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mental factors such as toxin. Our systematic network approach is
illustrated in Figure 1. Briefly, genes shared between PD and
T2DM were collected from several databases and mapped into the
human functional linkage network (FLN). We implemented a
random walk algorithm with restart (RWR) to rank the group of
genes shared between PD and T2DM. We further evaluated the
applicability of the network prioritization approach by testing the
most highly ranked gene as a potential diagnostic biomarker for
PD. In this study we identify SOD2 mRNA as a potential blood
biomarker that can be used to identify patients with PD.
Methods
Database mining and network analysis
We queried the DisGeNET database [17] that integrates
information from four respositories: Online Medelian Inheritance
in Man (OMIM), UniProt/SwissProte (UNIPROT), Pharmaco-
genomics Knowledge Base (PHARMGKB), and Comparative
Toxicogenomics Database (CTD). DisGeNET can be accessed
through the Cytoscape 2.8.3, a platform for complex network
analysis [18]. Search disease terms used in DisGeNET were the
following: Parkinson Disease (umls:C0030567), Diabetes Mellitus,
Type 2 (umls:C0011860). Disease-gene networks were retrieved
for PD and T2DM independently. Using the advanced network
merge option in Cytoscape, both PD and T2DM gene networks
were merged using gene ID as a matching attribute. Only shared
genes between both diseases were collected for further analysis.
The Disease and Gene Annotations database (DGA) [19] was
accessed through the web (http://dga.nubic.northwestern.edu/
pages/search.php). We searched for gene annotations shared
between PD and T2DM. Search disease terms in DGA were the
following: Parkinson’s disease, type 2 diabetes mellitus. Similarly,
we explored Human Experimental/Functional Mapper (HE-
FalMp) using the web-interface (http://hefalmp.princeton.edu/)
to investigate genetic associations between PD and T2DM [20].
Search disease terms used in HEFalMp were: Parkinson disease,
Diabetes Mellitus. A significance score of 10
25 was used as a cut-
off value for inclusion in the list of candidate genes. The Integrated
Complex Traits Networks interface (iCTNet), can be accessed
through the Cytoscape plugin [21]. This database allows the
automated construction of disease networks and integrates
phenotype-SNP, protein-protein interaction, disease-tissue, tissue-
gene and drug-gene interactions. Search disease terms were:
Parkinson’s disease, Diabetes Mellitus. We queried the disease-
gene networks associated with PD and T2DM using a cutoff p-
Figure 1. Integrative network approach. Well-characterized genes associated with PD (purple circles) and T2DM (magenta circles) were mapped
to the FLN and specified as training set. Shared genes between PD and T2DM (yellow circles) were collected from multiple databases and mapped to
the human FLN (black). A random walk algorithm with restart (RWR) was implemented to prioritize the list of shared genes between PD and T2DM
according to their distance to known disease genes and in terms of biological pathways involved. A highly ranked gene was evaluated as diagnostic
biomarker for PD on RNA samples from whole blood obtained from two independent clinical trials.
doi:10.1371/journal.pone.0109042.g001
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-5. Unlike DisGeNET, disease-gene networks are
merged automatically in iCTNet. Like in previous steps, only
shared genes between PD and T2DM were collected for further
analysis. A total of 84 genes shared between PD and T2DM were
collected from the aforementioned databases. Genetic associations
were manually curated after searching the literature in Pubmed.
Functional and gene ontology analysis was performed using
GENEMANIA plugin in Cytoscape [22]. In GENEMANIA, we
Figure 2. Biological functional analysis of candidate genes. Network of interactions among PD and T2DM shared genes, as retrieved by
GeneMANIA. Shared genes between PD and T2DM are displayed in yellow circles and other genes with the greatest number of interactions with
shared genes are displayed in gray circles. The size of the gray nodes represents the degree of association with the input genes (i.e., smaller size
represents low connectivity). The most represented pathways retrieved by GeneMANIA are displayed using GO annotations and Q-values of
significance.
doi:10.1371/journal.pone.0109042.g002
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greatest number of interactions, and advanced settings to include
physical, predicted, and genetic interactions, and interconnected
pathways.
Gene prioritization methods and cross-validation analysis
The list of 84 genes shared between PD and T2DM collected
from the databases was used for subsequent analysis using GPEC,
a Cytoscape 2.8.3 plugin that performs a RWR algorithm [23].
We used the default, weighted and undirected human FLN for this
analysis that contains 14,230 nodes and 263,884 links. Nodes
represent genes and each link represents the likelihood that the
connected genes participate in common biological processes. In
order to perform the gene prioritization in GPEC, we first
collected a list of well-characterized genes associated with PD and
T2DM and genes involved in the PD and T2DM KEGG
pathways (Table S2). Well-characterized genes known to be
associated with PD and T2DM were retrieved from the OMIM
(http://www.ncbi.nlm.nih.gov/omim), the Genetic association
database (GAD) (http://geneticassociationdb.nih.gov/) and
PDgene (http://www.pdgene.org/) (Table S2). Genes involved
in the PD and T2DM signaling pathways were retrieved from the
KEGG database (http://www.genome.jp/kegg/pathway.html).
As a first step in the prioritization, the list of well-characterized
genes associated with PD and the PD KEGG pathway was used as
a training set. The test set included the 84 genes shared between
both diseases and genes associated with T2DM and its associated
KEGG pathway. The training set was manually curated to ensure
that there was no overlap with any of the genes contained in the
test set. To perform the RWR, we set back-probability to 0.5 and
candidate genes were scored and ranked. As a second step, we
performed a series of prioritization steps with respect to the most
significant biological pathways retrieved by GENEMANIA. These
prioritization steps were performed for each individual pathway
independently. To this end, we collected the set of genes curated
for each biological pathway from the Broad Institute’s Molecular
Signatures Database (MSigDB) 3.0 [24] (Table S2). Here, the
training set consisted of genes curated for each pathway and the
test set consisted of the 84 genes shared between PD and T2DM.
In GPEC, we evaluated the performance of each prioritization
with a leave-one-out cross-validation (LOOCV) strategy where the
number of training genes is equal to the number of cross-validation
trials and one of the genes in the test set is held out during each
trial. As a result, a ROC curve of sensitivity versus 1-specificity is
built by the software. Since all the scores were determined by the
RWR algorithm, the final score for each gene was defined as the
sum of all individual scores obtained from each prioritization as
previously demonstrated using similar analyses [15,16,25]. The
overall workflow is presented in Figure 1.
Information about HBS and PROBE study participants
The Institutional Review Boards of Rosalind Franklin Univer-
sity of Medicine and Science approved the study protocol. Written
informed consent was received from all participants. We used 96
individuals including 50 PD patients (31 men, 19 women; Hoehn
and Yahr scale 1.9760.62; mean age at enrollment 63.1268.96;
mean age at onset 58.75610.17) and 46 healthy age-matched
controls (HC) (26 men, 20 women; mean age at enrollment
64.28610.42) enrolled in the HBS. Other clinical information is
reported in [15]. There were 5 PD and 5 HC patients with
T2DM. Details of patient and controls recruitment, clinical
assessments, and biobanking in the HBS study population have
been reported in part elsewhere [26] and http://www.
neurodiscovery.harvard.edu/research/biomarkers.html. As an in-
Table 1. Highly ranked RWR score-based genes.
Rank Gene Symbol Gene Name Score
1 SOD2 Superoxide dismutase 2 3.08E-03
2 MT-ND1 Mitochondrially encoded NADH dehydrogenase 1 2.93E-03
3 IFNG Interferon, gamma 2.90E-03
4 TNF Tumor necrosis factor 2.39E-03
5 TP53 Tumor protein p53 2.36E-03
6 IL6 Interleukin 6 2.16E-03
7 AKT1 V-akt murine thymoma viral oncogene homolog 1 1.96E-03
8 HNF4A Hepatocyte nuclear factor 4, alpha 1.80E-03
9 HMOX1 Heme oxygenase (decycling) 1 1.77E-03
10 FAS Fas (TNF receptor superfamily, member 6) 1.53E-03
11 APP Amyloid beta (A4) precursor protein 1.34E-03
12 CYP17A1 Cytochrome P450, family 17, subfamily A, polypeptide 1 1.23E-03
13 IGF1 Insulin-like growth factor 1 1.03E-03
14 PTGS2 Prostaglandin-endoperoxide synthase 2 1.02E-03
15 SOD1 Superoxide dismutase 1, soluble 9.80E-04
16 BDNF Brain-derived neurotrophic factor 8.46E-04
17 NOS2 Nitric oxide synthase 2 8.34E-04
18 TGM2 Transglutaminase 2 6.86E-04
19 GCH1 GTP cyclohydrolase 1 6.66E-04
20 UCHL1 Ubiquitin carboxyl-terminal esterase L1 6.60E-04
doi:10.1371/journal.pone.0109042.t001
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women; mean age at enrollment 63.1666.42; Hoehn and Yahr
scale 260.28) and 45 HC (24 male, 21 women; mean age at
enrollment 65.1268.60) enrolled in the PROBE Study
(#NCT00653783). There was one HC patient with T2DM.
Clinical diagnosis of PD was based on the United Kingdom
Parkinson’s Disease Society Brain Bank criteria. Healthy controls
had no history of neurological disease and a Mini-Mental State
Examination (MMSE) test score higher than 27. Inclusion and
exclusion criteria for patients enrolled in the PROBE study are
reported elsewhere in [27].
RNA isolation and real time polymerase chain reactions
Blood was collected and prepared as described using the
PAXgene Blood RNA system (Qiagen,Valencia, CA, USA)[28].
Samples with RNA integrity values . 7.0 and ratio of absorbances
at 260/280 nm between 1.7 and 2.4 were used in the current
study. Primer Express software (Life Technologies, Carlsbad, CA,
USA) was used to design the primers. The High Capacity RNA
transcription kit (Life Technologies, Carlsbad, CA, USA) was used
to reverse transcribe 1 mg of total RNA according to the
manufacturer’s protocol. The DNA engine Opticon 2 Analyzer
(Bio-Rad Life Sciences, Hercules, CA, USA) was used for the
qPCR reactions. Each 25 ml reaction contained Power SYBR (Life
Technologies, Carlsbad, CA, USA) and primers at a concentration
of 5 mM. Primer sequences used in qPCR assays are as follows:
GAPDH; forward: 59- CAACGGATTTGGTCGTATTGG-39;
reverse: 59- TGATGGCAACAATATCCACTTTACC-39,
SOD2; forward: 59- GTTCAATGGTGGTGGTCATATCA-39;
reverse: 59- GCAACTCCCCTTTGGGTTCT-39. Amplification
conditions and detailed description of qPCR experiments is
described in [15].
Statistical analysis
All analyses were performed with Prism4.0 (GraphPad, La Jolla,
CA, USA) and Statistica 8.0 (Statsoft, OK, Tulsa, USA). A student
t-test (two-tailed) was used to estimate the significance between PD
cases and controls for numerical variables. Linear regression and
Pearson correlation analysis was used to determine statistical
significance for the prospective biomarker adjusting for sex, age,
Hoehn & Yahr scale in both cohorts of patients and body mass
index (BMI) in the HBS study. A ROC curve analysis was used to
evaluate the diagnostic accuracy. A p-value less than 0.05 was
regarded statistically significant.
Results
Identification of shared genes between PD and T2DM
from disease-gene databases
We explored the DisGeNET database, a comprehensive
database of the human genetic associations related to disease
[17]. In DISGENET, the central node represents the disease and
the nodes linked to the central node represent genes that have
been associated to the queried disease. We queried the disease-
gene networks associated with both PD and T2DM. Analysis of
the merged network revealed a cluster consisting of 53 shared
genes between PD and T2DM (Table S1, Methods).
We next explored the DGA interface [19] and found 42
overlapping genes with the gene set collected in DisGeNET and 8
additional genes shared between PD and T2DM (Table S1). We
next interrogated the HEFalMp interface [20]. Similarly to DGA
and DisGeNET, we collected the shared genes between PD and
T2DM. The most significant genes in T2DM associated to PD
were HNF4A, PDX1, SLC2A4, and ABCC8 (Q,10
205)(Table
S1). Finally, we interrogated the iCTNet interface [21] that
contains results from 118 GWAS published studies and data from
the GWAS catalog. In iCTNet, we found 20 genes shared between
both diseases (Table S1). A total of 84 genes shared between PD
Figure 3. Evaluation of SOD2 as a potential biomarker for PD.
A. Relative abundance of SOD2 mRNA in blood of PD patients (black
circles) compared to healthy controls (white circles) in samples from the
HBS cohort. B. Replication of biomarker expression in an independent
set of samples from patients enrolled in the PROBE study. Relative
abundance of each biomarker was calculated using GAPDH as a
reference gene and healthy controls as calibrator. Error bars represent
standard error. C. ROC curve analysis to evaluate the diagnostic
accuracy of SOD2.
doi:10.1371/journal.pone.0109042.g003
SOD2 mRNA Is a Biomarker for Parkinson’s Disease
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e109042and T2DM were collected from the aforementioned databases and
used for further analysis.
To further identify the potential functional implications in the
cluster of genes shared between PD and T2DM, we imported all
84 genes into GeneMANIA [22]. Analysis of the 84 shared genes
identified the most overrepresented pathways including nitric
oxide biosynthetic processing, carbohydrate and lipid metabolic
processing, insulin secretion, regulation of glucose, and inflamma-
tion (Figure 2).
Gene prioritization and experimental validation
Given the numerous molecular links between PD and T2DM,
we investigated the extent to which genes identified as shared
between PD and T2DM can be used to classify patients with PD.
This idea is particularly salient in light of the recent finding that
revealed that genes identified in shared molecular networks
between PD and T2DM may improve the clinical diagnosis of
PD. Accordingly, APP was identified in a functional network
shared between well-characterized genes associated with PD and
T2DM. APP mRNA was capable to distinguish PD patients from
HC with 80% accuracy [15], a diagnostic capacity that extends
beyond the one afforded by the current clinical diagnostic criteria
[29,30].
We implemented a candidate prioritization approach using a
RWR algorithm within the human the FLN described previously
[15,16,25,31]. This algorithm measures the closeness of potentially
candidate genes to confirmed genes within the FLN or protein-
protein interaction network. We used GPEC, a cytoscape plugin
for RWR-based gene prioritization [23] to rank 84 candidates
collected from the curated databases (Table S1). In the RWR
algorithm, the known disease genes are mapped to the FLN and
specified as ‘‘training set’’ and the ‘‘test set’’ containing potential
candidates can be ranked according to their closeness to the
training genes within the FLN (See Methods). The training set
consisted of well-characterized genes associated with PD and its
KEGG associated pathway. The test set included the list of 84
shared genes and well-characterized genes associated with T2DM
and its KEGG associated pathway. RWR score-based genes are
listed in Table S3. Further, we evaluated the performance of the
gene prioritization using a LOOCV strategy (see Methods).
LOOCV represented in terms of receiver operating characteristic
curve (ROC) resulted in an area under curve AUCPD-T2DM value
of 0.85 (Figure S1A).
As a second step, we prioritized the list of 84 shared genes with
respect to the most significant biological pathways determined by
GeneMania (see Methods). We collected the set of genes curated
for each biological pathway from the Broad Institute’s Molecular
Signatures Database 3.0 (MSigDB) [24] (Table S2). These gene
sets were used as training sets during each prioritization. Gene
prioritization was performed in GPEC for each individual
pathway independently (Methods, Table S3). LOOCV performed
for each prioritization resulted in AUC values ranging from 0.90–
0.99 (Figure S1B-E). The top RWR score-based genes are listed in
Table 1. The complete list of RWR score-based candidate genes
according to each prioritization step is provided in (Table S3).
In order to validate the results obtained from the network
analysis we evaluated the most highly ranked gene, SOD2,a sa
potential biomarker for PD. Relative abundance of SOD2 mRNA
was measured in whole blood of PD patients compared to HC
from samples obtained from two independent clinical trials, HBS
and PROBE. Quantitative PCR assays revealed that SOD2
mRNA is significantly upregulated in blood of PD patients
compared to HC in both cohorts of study participants, although
significant overlap in expression levels was observed between PD
and controls (Figure 3A and B). To evaluate the diagnostic
accuracy of SOD2 in distinguishing PD patients from HC, ROC
curve analysis was performed. As shown in Figure 3C, the AUC
values for SOD2 was 0.69.
Pearson correlation analysis demonstrated that relative abun-
dance of SOD2 was independent of other covariates including age
(r=20.13, p=0.40), and sex (r=20.03, p=0.79) in both cohorts
of patients and BMI (r=0.18, p=0.21) in the HBS cohort.
Correlation analysis of SOD2 mRNA expression and Hoehn and
Yahr stage was not significant (r=0.04, p=0.73). Correlation with
medication was not determined since most of the patients with PD
were medicated with several drugs and the number of untreated
patients was too small to reliably detect a significant change.
Discussion
We have recently demonstrated that shared molecular networks
between PD and T2DM can be exploited to identify highly
accurate biomarkers for PD [15]. This result along with other
studies investigating the relationship between PD and T2DM
suggested that a system-level understanding of the comorbidity
between both diseases might improve the clinical management of
PD and may elucidate potential therapeutic targets [5,13].
In our previous study the network analysis was restricted to the
intersection of genes between PD and T2DM identified by
GWAS. However, this approach is limited given that a large
number of genes fail to exceed the genome-wide statistical
threshold of significance and are therefore neglected. One
example was the failure to recognize the association of a
polymorphism in PPARG in T2DM by other studies because of
its modest effect on susceptibility for T2DM [34]. In addition, very
few causative genes of disease have been proven to be useful for
clinical diagnosis [35]. For example, mutations in LRRK2 and DJ-
1 are implicated in hereditary PD, but changes in their mRNA or
protein expression levels in blood may not be useful diagnostic
biomarkers for early stage PD [36,37]. Here we expanded our
analysis to integrate data from publicly available databases that
includes a wide range of experimental designs including but not
limited to pharmacogenomics, toxicogenomics, and other exper-
iments in addition to GWAS.
We identified 84 genes shared between PD and T2DM by
interrogating several disease-gene databases. Biological and
functional analysis of these genes identified shared dysregulated
pathways including nitric oxide biosynthesis, regulation of glucose,
lipid and carbohydrate metabolism, insulin secretion and inflam-
mation. Shared genes between both diseases were prioritized using
a RWR within the human FLN. Not surprisingly, highly ranked
genes were representative of the most significant dysregulated
pathways. For example, AKT1, IGF1 and TP53 are involved in
insulin signaling and glucose homeostasis [38,39]. In this regard,
dysregulation of glucose metabolism was identified as an early
event in sporadic PD and it has been hypothesized that alpha
synuclein (SNCA) may play a role in this process [40]. In addition,
genes associated with inflammation including TNF and IL6 are
among the most highly ranked genes. In this context, neuroin-
flammation is associated with the pathophysiology of PD [41,42].
HNF4A was also among the top 10 genes in the prioritized list.
Interestingly, HNF4A may also play a role in intestinal lipid
metabolism, oxidative stress and inflammation, processes that are
implicated in both chronic diseases [43]. Collectively, these
findings are consistent with previous studies that highlight the
significant convergence of dysregulated pathways in PD and
T2DM [4,15,44].
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patients with PD from two independent cohorts of study
participants. Relative abundance of SOD2 was upregulated in
blood of PD patients compared to healthy individuals. SOD2 is a
mitochondrial enzyme that protects against oxidative stress by
converting superoxide radicals to molecular oxygen and hydrogen
peroxide. Given its antioxidant capacity, it has been implicated in
the pathogenesis of PD. For example, inactivation of SOD2
increases mitochondrial ROS production in in vitro models of PD
[45]. Moreover, SOD2 protein levels are increased in the frontal
cortex of PD patients [46]. In the context of diabetes, increased
levels of SOD2 mRNA have been found in skeletal muscle of
patients with T2DM [47]. In addition, SOD2 has been associated
to be involved in inflammation [48], insulin signaling and glucose
metabolism[49,50], and lipid metabolism and peroxidation [51],
processes that were identified dysregulated in the network analysis.
Therefore, it is not surprising that SOD2 was the most highly
ranked gene by the prioritization method.
Recently, drugs to treat diabetic patients, metformin-sulfonyl-
urea and exenatide have shown promise in PD patients [52,53]. In
fact, improvement of motor and cognitive functions persists one
year after the treatment with exenatide [54]. Interestingly, diabetic
drugs are known to interact with SOD2. For example, metformin
treatment results in an increased expression of SOD2 mRNA in
human endothelial cells [55]. Troglitazone treatment, another
anti-diabetic and anti-inflammatory drug, results in decreased
expression of SOD2 mRNAs in cellular models [56,57]. In
addition, gliclazide treatment, an oral sulfonylurea hypoglycemic
agent, results in decreased protein expression of SOD2 [58], and
rosiglitazone, an insulin sensitizer, increased SOD2 protein
expression in retinal cells from mice [59]. Based on these
observations, expression of SOD2 in blood may be useful to
evaluate the therapeutic effect of anti-diabetic drugs in PD
patients.
This study has several strengths and limitations. Biomarkers
obtained from microarray studies may be data set specific and not
indicative of the underlying disease pathology. In this context, our
integrated network approach provides a framework to identify and
prioritize PD biomarkers involved in common dysregulated
pathways. Another strength is the replication of this biomarker
in two independent cohorts of patients. However, there are several
limitations and potential confounding factors. For example,
although we have found that GAPDH mRNA expression in
blood is stable in previous studies [15,16,27,60], replication of this
biomarker using several reference genes for normalization is
desirable [61]. In addition, differences in blood counts and PD
medications may bias gene expression results. Thus, evaluation of
SOD2 mRNA in drug-naı ¨ve PD patients and in a large well-
characterized prospective study will be important to determine its
clinical utility.
In summary, our study demonstrates that integration of shared
molecular networks provides a useful framework to prioritize
candidate biomarkers in a biologically relevant context. Remark-
ably, we demonstrate that expression of a highly ranked gene
identified within shared dysregulated pathways can be used as
diagnostic marker for PD. We foresee integrated network
approaches will provide a better understanding of the underlying
disease mechanism and facilitate the discovery of accurate
biomarkers and therapeutic targets. In this regard, a network-
based approach was useful to identify a neuroprotective agent,
alvespimycin (17-DMAG), in PD [25]. Although the prioritization
method presented in this study has been evaluated in the specific
case of PD-T2DM, other disease-disease associations may be
studied following this protocol. For instance, the construction of
shared genes and protein networks have facilitated the under-
standing of other disease-disease associations such as asthma and
tuberculosis [32] and artherosclerosis-induced ocular diseases [33].
Thus, network analysis of disease comorbidities may reveal novel
diagnostic biomarkers and therapeutic strategies.
Future studies will be aimed to replicate these findings in
samples from non-medicated and patients at risk of PD and to
evaluate other potential candidate biomarkers found in this study.
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Figure S1 Validation of each prioritization step. The
performance of each prioritization step was validated by
computing values for ROC and AUC through the leave-one-out
validation method using GPEC.
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